NCI宣布开始投资新计划用以寻找进行癌症研究的组织来源位点

  近日，来自美国国家癌症研究所临床蛋白质组学研究办公室宣布他们正在寻找组织来源的精确位点。
  这些位点可以被国家癌症研究所临床蛋白质组肿瘤分析团队（CPTAC）进行蛋白组学的步骤优化来收集人类原发性的肿瘤。
  CPTAC首先利用NCI癌症基因组图谱研究团队进行过基因组和转录组特性研究的肿瘤组织样本，对这些肿瘤样本进行了蛋白质生物标志物的发现及证实研究；在该计划的第一个阶段研究者主要对三种类型的肿瘤：乳腺癌、结直肠癌和卵巢癌进行分析研究。
  来自NCI的研究者表示，在下一个阶段我们的目的是调查额外的癌症类型，这些癌症类型在其基因组和蛋白质组之间的复杂性的问题上依然没有得到解答，而这或许需要获得高质量、临床上标注的、原发性及未经过处理的肿瘤样本。（转化医学网360zhyx.com）
  以上为转化医学网原创翻译整理，转载请注明出处和链接！
转化医学网推荐的新闻阅读：

NCI Announces Funding Opportunity for Tissue Source Sites

The National Cancer Institute's Office of Cancer Clinical Proteomics Research has announced it is seeking Tissue Source Sites.

These sites will prospectively collect primary human tumors according to a protocol optimized for proteomics for the NCI's Clinical Proteomic Tumor Analysis Consortium (CPTAC).

The CPTAC initiative has done protein biomarker discovery and verification studies in tumor tissue samples previously characterized at the genomic and transcriptomic level by the NCI's Cancer Genome Atlas (TCGA) team. In the first phase of the project, participating researchers undertook analysis of three tumor types — breast, colorectal, and ovarian.

In the next phase of the project the consortium aims to investigate "additional cancer types where questions remain unanswered on the complexity between the proteome and the genome in cancer," the NCI said, adding that this would require "acquisition of high-quality, clinically annotated, primary, and untreated tumor specimens."